Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, BTIG Research Analyst Says

Bicara Therapeutics (NASDAQ:BCAX) had its target price boosted by analysts at BTIG Research from $28.00 to $39.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 64.14% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Guggenheim assumed coverage on shares of Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 price target for the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $39.00 price objective on shares of Bicara Therapeutics in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. The Goldman Sachs Group increased their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $31.45.

Bicara Therapeutics Trading Down 14.3%

Bicara Therapeutics stock opened at $23.76 on Wednesday. Bicara Therapeutics has a twelve month low of $9.67 and a twelve month high of $30.99. The stock has a 50 day moving average of $25.90 and a two-hundred day moving average of $21.69. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -8.55 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). Equities analysts predict that Bicara Therapeutics will post -3.42 earnings per share for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer directly owned 182,177 shares in the company, valued at approximately $5,279,489.46. This trade represents a 13.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total value of $807,800.00. Following the sale, the chief financial officer directly owned 129,855 shares in the company, valued at $3,746,316.75. This trade represents a 17.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 88,450 shares of company stock valued at $2,366,675. Corporate insiders own 13.80% of the company’s stock.

Institutional Trading of Bicara Therapeutics

A number of institutional investors have recently bought and sold shares of BCAX. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at $45,000. Legal & General Group Plc boosted its position in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares in the last quarter. Larson Financial Group LLC grew its stake in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.